36396-99-3
36396-99-3
Chemical Structure
N6-Cyclohexyladenosine
Synonym(s): CHA
- CAS No.: 36396-99-3
- Formula:C16H23N5O4
- Molecular Weight:349.38
IUPAC Name: (2R,3R,4S,5R)-2-(6-(cyclohexylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
InChIKey: SZBULDQSDUXAPJ-XNIJJKJLSA-N
SMILES: OC[C@@H]1[C@H]([C@H]([C@H](N2C=NC3=C2N=CN=C3NC4CCCCC4)O1)O)O
Biological Activity: N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC50 = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N6-Cyclohexyladenosine | 99.79% | N6-Cyclohexyladenosine is a selective adenosine A1 receptor agonist (EC50 = 8.2 nM). N6-Cyclohexyladenosine enhances the activation of the PI3K/Akt/CREB/BDNF axis. N6-Cyclohexyladenosine promotes remyelination, induces sleep, and improves 3-NP-induced Huntington's disease. N6-Cyclohexyladenosine can be used in liver cancer research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SDZ-WAG994 | SDZ-WAG994 (WAG-994) is a stable, long-acting, selective and orally active A1-adenosine receptor agonist with a KD of 23 nM. SDZ-WAG994 can be used for the research of atrial fibrillation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N6-Cyclopentyladenosine | 99.95% | N6-Cyclopentyladenosine (CPA) is a selective Adenosine A1 receptor agonist, with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. N6-cyclopentyladenosine increases Apoptosis. N6-Cyclopentyladenosine has antitumor activity against leukemia. N6-cyclopentyladenosine improves 5-fluorouracil (HY-90006)-induced hematopoietic damage, regulates sleep, and delays Aminophylline-induced clonic epileptic seizures. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CCPA (Standard) | ≥98% | CCPA (2-Chloro-N6-cyclopentyladenosine (Standard)) is the analytical standard of CCPA (HY-103185). This product is intended for research and analytical applications. CCPA (2-Chloro-N6-cyclopentyladenosine) a highly selective A1 adenosine receptors agonist with a Ki of 0.4 nM. CCPA inhibits adenylate cyclase with an IC50 of 33 nM. CCPA exhibits anti-seizure and cardiacprotective activity. CCPA can be used for the research of seizure and myocardial infarction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Trabodenoson | 99.97% | Trabodenoson (INO-8875), an adenosine mimetic, is a highly selective Adenosine A1 receptor agonist. Trabodenoson (INO-8875) is used in the study for Primary Open-Angle Glaucoma. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DTI 0009 | DTI 0009 is a selective adenosine A1 receptor agonist used to reduce heart rate in patients with atrial fibrillation and to treat arrhythmias. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N6-Ethyladenosine | 99.90% | N6-Ethyladenosine is an adenosine derivative, acts as a Adenosine receptor agonist, with Kis of 4.9 and 4.7 nM for hA1AR and hA3AR, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N6-iso-Propyladenosine | N6-iso-Propyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2’-Deoxy-N6-cyclopentyladenosine | 2’-Deoxy-N6-cyclopentyladenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GR79236 | 99.89% | GR79236 is a highly potent, selective and orally active adenosine A1 receptor agonist with a Kis of 3.1 nM and 1300 nM for A1 and A2 receptors, respectively. GR79236 has anti-nociceptive and anti-inflammatory actions. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tecadenoson | 99.69% | Tecadenoson (CVT-510) is a selective A1 adenosine receptor agonist. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Asghari AA, et al. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, protects myelin and induces remyelination in an experimental model of rat optic chiasm demyelination; electrophysiological and histopathological studies. J Neurol Sci. 2013 Feb 15;325(1-2):22-28. [Content Brief]
- [2]. Blanco-Centurion C, et al. Adenosine and sleep homeostasis in the Basal forebrain. J Neurosci. 2006 Aug 2;26(31):8092-100. [Content Brief]
- [3]. Nikodijević O, et al. Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Lett. 1990 Feb 12;261(1):67-70. [Content Brief]
- [4]. Nakashima J, et al. Increased erythropoietin secretion in human hepatoma cells by N6-cyclohexyladenosine. Am J Physiol. 1991 Sep;261(3 Pt 1):C455-60. [Content Brief]
- [5]. Churchill PC, et al. Renin secretory effects of N6-cyclohexyladenosine: effects of dietary sodium. Am J Physiol. 1987 May;252(5 Pt 2):F872-6. [Content Brief]
- [6]. Rabie MA, et al. Adenosine A1 receptor agonist, N6-cyclohexyladenosine, attenuates Huntington's disease via stimulation of TrKB/PI3K/Akt/CREB/BDNF pathway in 3-nitropropionic acid rat model. Chem Biol Interact. 2023 Jan 5;369:110288. [Content Brief]
- [7]. Liddle LJ, et al. An Assessment of Physical and N6-Cyclohexyladenosine-Induced Hypothermia in Rodent Distal Focal Ischemic Stroke. Ther Hypothermia Temp Manag. 2024 Mar;14(1):36-45. [Content Brief]
